Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialResearch in context

Summary: Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and phagocytosis compared to rituximab. Our aim was t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers, Loretta J. Nastoupil
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-08-01
coleção:	EClinicalMedicine
Assuntos:	Follicular lymphoma Lenalidomide Obinutuzumab Relapsed
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537024003262
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!